Analyst Increases Price Target for Madrigal Pharmaceuticals Maintains Strong Buy Recommendation
According to Citigroup analyst David Lebovitz, Madrigal Pharmaceuticals (NASDAQ: MDGL) continues to be a strong buy as of March 15, ...
Tag: MDGL
Analysts Bullish on Madrigal Pharmaceuticals with Price Target Upgrades
Madrigal Pharmaceuticals shares are on the rise following an increase in price target by HC Wainwright & Co. to $405. ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Institutional Investors Rally Behind GXO Logistics
